# Methylene Blue-Enhanced Ultrafiltration Improves Outcomes After Cardiopulmonary Bypass

> **NCT07212842** · PHASE2 · COMPLETED · sponsor: **University of Sao Paulo** · enrollment: 124 (actual)

## Conditions studied

- Cardiopulmonary Bypass Surgery
- Aortic Valve Surgery
- Mitral Valve Surgery
- Myocardial Revascularization Surgery With Extracorporeal Circulation

## Interventions

- **DRUG:** Methylene Blue
- **PROCEDURE:** Conventional ultrafiltration
- **PROCEDURE:** Zero-balance ultrafiltration

## Key facts

- **NCT ID:** NCT07212842
- **Lead sponsor:** University of Sao Paulo
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-12
- **Primary completion:** 2023-08-25
- **Final completion:** 2024-03-16
- **Target enrollment:** 124 (ACTUAL)
- **Last updated:** 2025-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07212842

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07212842, "Methylene Blue-Enhanced Ultrafiltration Improves Outcomes After Cardiopulmonary Bypass". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT07212842. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*